I have just read a news, which can be filled with hope to many old people, around the world: They test successfully in mice a molecule to treat Alzheimer's.
The news said that a team of researchers has succeeded, in proving successful, in mouse models of Alzheimer's disease, a molecule, that has been shown to have a neuroprotective effect in these animals.
The multitarget molecule ASS234 has been created by researchers, at the Universitat Autònoma de Barcelona (UAB), from the Higher Council for Scientific Research (CSIC) and from the University of Barcelona (UB), that they have tested in transgenic mice, experimental model of alzheimer.
The molecule ASS234 inhibits the enzymes monoamine oxidase (A and B), acetylcholinesterase and butyryl cholinesterase, implicated in biochemical processes, underlying to neurodegenerative disorders.
The molecule has been developed as a hybrid of two known molecules. One is the donepezil, currently used in the treatment of this neurodegenerative disease.
The other one: the compound PF9601N, an inhibitor of the enzyme monoamine oxidase B (MAO B), patented and developed by the same researchers, at UAB and CSIC, with neuroprotective effects, proven in different experimental models of Parkinson's disease.
The molecule ASS234 stimulates cholinergic and monoaminergic transmission antiapotótico shows an antioxidant effect and it is capable of reduce oligomer formation of beta-amyloid, reducing the number of amyloid plaques, in transgenic mice.
Also, the molecule shows a short positive effect, on the recovery of memory, in mice injured with scopolamine.
After synthesis and design of the molecule, it has been biologically evaluated and confirmed, as a potential therapeutic agent, in Alzheimer's disease. It has also been characterized its biochemical activity and pharmacological potential and has conducted its synthesis and molecular modeling studies.
The researchers, responsible for these processes, work for years in the design, synthesis and biological evaluation of new multipotent molecules capable of interacting with multiple cellular targets involved in Alzheimer's.
The Patent of the ASS234 molecule has, recently, been approved in the United States through the Spanish company Inurrieta Integral Consulting and is currently in phase introduced to different groups of pharmaceutical companies.
The Alzheimer's is a neurological disorder, with a high incidence in the elderly. It presents a complex neurodegenerative disease, that involves progressive loss of cognitive capacity (memory, language, learning), accompanied by psychiatric disorders (anxiety, depression, apathy, aggression).
Although, not yet, it is known why it occurs, although senile plaques, neurofibrillary tangles, the oxidative damage, in different cell structures, and low levels of the neurotransmitter acetylcholine are agents of great importance, in the development of this pathology.
Well, I hope this discovery is a reality, in the next future and it let many old people living a good life, at the end of their lives.
And I hope that you have liked to read this news.
Until my next post, kind regards,
Luis.
Sponsored by Costaluz Lawyers.
Please cick below:
